Gender

Male

Female

N (%)

143 (57.2%)

107 (42.8%)

Age at time of RT (mean +SD y)

69 ±10.9

Radiation field

Cervical

Cervicothoracic

Thoracic

Thoracolumbal

Lumbal

Multiple locations

16 (6.4%)

11 (4.4%)

91 (36.4%)

30 (12%)

84 (33.6%)

18 (7.2%)

Radiation dose

1x8 Gy

5x4 Gy

10x3 Gy

13x3Gy

166 (66.4%)

76 (30.4%)

6 (2.4%)

2 (0.8%)

Treatment

RT only

RT and surgery

242 (96.8%)

8 (3.2%)

VAS pretreatment (mean SD cm)

valid

missing

6.5±2.4

176 (70.4%)

74 (29.6%)

Number spinal metastases

1 or 2

multiple

107 (42.8%)

143 (57.2%)

Visceral metastases

present

not present

96 (38.4%)

154 (61.6%)

Brain metastases

present

not present

11 (4.4%)

239 (95.6%)

Lymphogenic metastases

present

not present

114(45.6%)

136(54.4%)

Clinical profile

Favorable

Moderate

Unfavorable

50 (20%)

71 (28.4%)

129 (51.6%)

Breast cancer (total N=49)

Hormone receptorstatus

ER/PR positive, Her2 positive

ER/PR positive, Her2 negative

ER/PR negative, Her2 positive

ER/PR negative, Her2 negative

ER+/PR-, Her2 negative

ER+/PR-, Her2 postive

ER+/PR+, Her2 unknown

ER negative, Pr+, Her2 negative

4 (1.6%)

28 (11.2%)

2 (0.8%)

3 (1.2%)

9 (3.6%)

1 (0.4%)

1 (0.4%)

1 (0.4%)

Lung cancer type

(total N=76)

NSCLC

SCLC

not defined

62 (81.6%)

12 (15.8%)

2 (2.6%)

EGFR/ALK mutation NSCLC

present

not present

unknown

KRAS mutation

NSCLC

present

not present

unknown

6 (9.6%)

24 (38.7%)

32 (51.6%)

18 (29%)

8 (13%)

36 (58%)

KPS

80-100

10-70

105 (42%)

145 (58%)